"And then maybe if I could just tack on. In C3G, we've had reasonably promising Phase II data from avacopan in the ACCOLADE study in December. The company there is talking about potential for filing. That would put you very significantly behind. So just timings and indeed differentiation on that side of things as well would be helpful."